The interaction between endothelin-1 and nitric oxide in the vasculature: New perspectives

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 300, Issue 6, 2011, Pages 1288-1295

  Bourque, Stephane L ^a   Davidge, Sandra T ^a   Adams, Michael A ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; NITRIC OXIDE;

BIOAVAILABILITY; DOWNSTREAM PROCESSING; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION; VASOCONSTRICTION;

ANIMALS; BLOOD VESSELS; ENDOTHELIN-1; HUMANS; MODELS, ANIMAL; NITRIC OXIDE; SIGNAL TRANSDUCTION; VASCULAR DISEASES; VASOCONSTRICTION;

EID: 79958828644     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00397.2010     Document Type: Review

References (104)

1. Allcock GH, Warner TD, Vane JR. Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists. Br J Pharmacol 116: 2482-2486, 1995.
2. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 8: 107-115, 2003.
3. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110: 2233-2240, 2004.
4. Balwierczak JL. Two subtypes of the endothelin receptor (ETA and ETB) mediate vasoconstriction in the perfused rat heart. J Cardiovasc Pharmacol 22, Suppl 8: S248-S251, 1993.
5. Bank N, Aynedjian HS, Khan GA. Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension 24: 322-328, 1994.
6. Banting JD, Friberg P, Adams MA. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J Hypertens 14: 975-981, 1996.
7. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86: 485-498, 2008.
8. Black SM, Fineman JR. Oxidative and nitrosative stress in pediatric pulmonary hypertension: roles of endothelin-1 and nitric oxide. Vascul Pharmacol 45: 308-316, 2006.
9. Bohm F, Pernow J, Lindstrom J, Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 104: 143-151, 2003.
10. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587-590, 1990.
11. Bourque SL, Whittingham HA, Brien SE, Adams MA. Inhibition of ET-1 signaling is a critical component of nitric oxide-mediated acute regulation of arterial pressure (Abstract). Hypertension 54: P446, 2009.
12. Bras-Silva C, Leite-Moreira AF. Myocardial effects of endothelin-1. Rev Port Cardiol 27: 925-951, 2008.
13. Callera G, Tostes R, Savoia C, Muscara MN, Touyz RM. Vasoactive peptides in cardiovascular (patho)physiology. Expert Rev Cardiovasc Ther 5: 531-552, 2007.
14. Cardillo C, Kilcoyne CM, Cannon RO III, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 35: 1237-1241, 2000.
15. Chen M, Todd-Turla K, Wang WH, Cao X, Smart A, Brosius FC, Killen PD, Keiser JA, Briggs JP, Schnermann J. Endothelin-1 mRNA in glomerular and epithelial cells of kidney. Am J Physiol Renal Fluid Electrolyte Physiol 265: F542-F550, 1993.
16. Clozel M, Breu V. The role of ETB receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ETB receptor antagonist Ro 46-8443. FEBS Lett 383: 42-45, 1996.
17. Cowley AW Jr, Mori T, Mattson D, Zou AP. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 284: R1355-R1369, 2003.
18. Dammanahalli KJ, Sun Z. Endothelins and NADPH oxidases in the cardiovascular system. Clin Exp Pharmacol Physiol 35: 2-6, 2008.
19. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 160: 297-304, 2002.
20. 125I]endo-thelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol 13, Suppl 5: S166-S170, 1989.
21. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85: 9797-9800, 1988.
22. Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clin Exp Hypertens 15: 527-537, 1993.
23. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145: 323-333, 2005.
24. Erley CM, Rebmann S, Strobel U, Schmidt T, Wehrmann M, Oss-wald H, Risler T. Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. Exp Nephrol 3: 293-299, 1995.
25. Evans RG, Majid DS, Eppel GA. Mechanisms mediating pressure natriuresis: what we know and what we need to find out. Clin Exp Pharmacol Physiol 32: 400-409, 2005.
26. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85: 906-911, 1999.
27. Filep JG. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. Hypertension 30: 22-28, 1997.
28. Fujihara CK, De Nucci G, Zatz R. Do ETA receptors participate in the hemodynamic and renal effects of chronic nitric oxide blockade? J Cardiovasc Pharmacol 26, Suppl 3: S462-S465, 1995.
29. Fujita K, Matsumura Y, Miyazaki Y, Takaoka M, Morimoto S. Role of endothelin-1 in hypertension induced by long-term inhibition of nitric oxide synthase. Eur J Pharmacol 280: 311-316, 1995.
30. Gellai M, Fletcher T, Pullen M, Nambi P. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol Regul Integr Comp Physiol 271: R254-R261, 1996.
31. Goel A, Su B, Flavahan S, Lowenstein CJ, Berkowitz DE, Flavahan NA. Increased endothelial exocytosis and generation of endothelin-1 contributes to constriction of aged arteries. Circ Res 107: 242-251, 2010.
32. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF. Termination of endothelin signaling: role of nitric oxide. J Cell Physiol 158: 485-494, 1994.
33. Gratton JP, Cournoyer G, Loffler BM, Sirois P, D'Orleans-Juste P. ETB receptor and nitric oxide synthase blockade induce BQ-123-sensi-tive pressor effects in the rabbit. Hypertension 30: 1204-1209, 1997.
34. Guarda E, Myers PR, Brilla CG, Tyagi SC, Weber KT. Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Car-diovasc Res 27: 1004-1008, 1993.
35. Guyton AC, Hall JE, Lohmeier TE, Jackson TE, Kastner PR. Blood pressure regulation: basic concepts. Fed Proc 40: 2252-2256, 1981.
36. Hanson GC, Andersson KE, Gyllstedt E, Hogestatt ED, Lindberg BF. Hydrolysis of big endothelin-1 by a serine protease in the membrane fraction of human lung. Regul Pept 68: 63-69, 1997.
37. Harrison VJ, Barnes K, Turner AJ, Wood E, Corder R, Vane JR. Identification of endothelin 1 and big endothelin 1 in secretory vesicles isolated from bovine aortic endothelial cells. Proc Natl Acad Sci USA 92: 6344-6348, 1995.
38. Hay DW, Luttmann MA, Beck G, Ohlstein EH. Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchus. Br J Pharmacol 118: 1209-1217, 1996.
39. Hayasaki-Kajiwara Y, Naya N, Shimamura T, Iwasaki T, Nakajima M. Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells. Br J Pharmacol 127: 1415-1421, 1999.
40. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 11: 1375-1380, 1993.
41. Haynes WG, Strachan FE, Gray GA, Webb DJ. Forearm vasocon-striction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. J Cardiovasc Pharmacol 26, Suppl 3: S40-S43, 1995.
42. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852-854, 1994.
43. Hexum TD, Hoeger C, Rivier JE, Baird A, Brown MR. Characterization of endothelin secretion by vascular endothelial cells. Biochem Biophys Res Commun 167: 294-300, 1990.
44. 125I]endothelin-1 binding sites: autoradiographic studies in the brain and periphery of various species including humans. J Cardiovasc Pharmacol 13, Suppl 5: S162-S165, 1989.
45. Humbert M, Montani D, Perros F, Dorfmuller P, Adnot S, Eddahibi S. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol 49: 113-118, 2008.
46. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 91: 4892-4896, 1994.
47. Iwasaki T, Hayasaki-Kajiwara Y, Shimamura T, Naya N, Nakajima M. Endothelin receptor subtype antagonist activity of S-0139 in various isolated rabbit and canine arteries. Eur J Pharmacol 400: 255-262, 2000.
48. Kaw S, Hecker M, Southan GJ, Warner TD, Vane JR. Characterization of serine protease-derived metabolites of big endothelin in the cytosolic fraction from human polymorphonuclear leukocytes. J Cardiovasc Pharmacol 20, Suppl 12: S22-S24, 1992.
49. Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, Webb DJ. Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol 88: 644-651, 2010.
50. Khimji AK, Rockey DC. Endothelin-biology and disease. Cell Signal 22: 1615-1625, 2010.
51. Kloog Y, Ambar I, Sokolovsky M, Kochva E, Wollberg Z, Bdolah A. Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science 242: 268-270, 1988.
52. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 92: 99-104, 1993.
53. Kuchan MJ, Frangos JA. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol Heart Circ Physiol 264: H150-H156, 1993.
54. Labonte J, Brochu I, Simard E, D'Orleans-Juste P. Distinct modulation of the endothelin-1 pathway in iNOS-/- and eNOS-/- mice. Can J Physiol Pharmacol 86: 516-525, 2008.
55. Labonte J, D'Orleans-Juste P. Enhanced or repressed pressor responses to endothelin-1 or IRL-1620, respectively, in eNOS knockout mice. J Cardiovasc Pharmacol 44, Suppl 1: S109-S112, 2004.
56. Levin ER. Endothelins. N Engl J Med 333: 356-363, 1995.
57. Little PJ, Ivey ME, Osman N. Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. Curr Vasc Pharmacol 6: 195-203, 2008.
58. Malek AM, Greene AL, Izumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci USA 90: 13:5999-6003, 1993.
59. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation 84: 1457-1468, 1991.
60. Mazzocchi G, Rossi GP, Malendowicz LK, Champion HC, Nussdor-fer GG. Endothelin-11-31, acting as an ETA-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells. FEBS Lett 487: 194-198, 2000.
61. Mitsutomi N, Akashi C, Odagiri J, Matsumura Y. Effects of endogenous and exogenous nitric oxide on endothelin-1 production in cultured vascular endothelial cells. Eur J Pharmacol 364: 65-73, 1999.
62. Moncada S, Rees DD, Schulz R, Palmer RM. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 88: 2166-2170, 1991.
63. Morbidelli L, Orlando C, Maggi CA, Ledda F, Ziche M. Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol Heart Circ Physiol 269: H686-H695, 1995.
64. Morton JJ, Beattie EC, Speirs A, Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens 11: 1083-1088, 1993.
65. 125I]atrial natriuretic peptide in rat tissue: a comparative study. J Cardiovasc Pharmacol 13, Suppl 5: S67-S74, 1989.
66. Nishiyama M, Takahara Y, Masaki T, Nakajima N, Kimura S. Pharmacological heterogeneity of both endothelin ETA- and ETB-recep-tors in the human saphenous vein. Jpn J Pharmacol 69: 391-398, 1995.
67. Niwa Y, Nagata N, Oka M, Toyoshima T, Akiyoshi H, Wada T, Nakaya Y. Production of nitric oxide from endothelial cells by 31-amino-acid-length endothelin-1, a novel vasoconstrictive product by human chymase. Life Sci 67: 1103-1109, 2000.
68. Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, Goligorsky MS. Permissive role of nitric oxide in endothelin-induced migration of endo-thelial cells. J Biol Chem 272: 1747-1752, 1997.
69. Opgenorth TJ, Wessale JL, Dixon DB, Adler AL, Calzadilla SV, Padley RJ, Wu-Wong JR. Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level. J Cardiovasc Pharmacol 36, Suppl 1: S292-S296, 2000.
70. Palmer MJ. Leads for the treatment of pulmonary hypertension. Expert Opin Ther Pat 19: 575-592, 2009.
71. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1987.
72. Pollock DM. Chronic studies on the interaction between nitric oxide and endothelin in cardiovascular and renal function. Clin Exp Pharmacol Physiol 26: 258-261, 1999.
73. Pollock DM, Polakowski JS. ETA receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat. J Am Soc Nephrol 8: 1054-1060, 1997.
74. Pollock DM, Polakowski JS, Opgenorth TJ, Pollock JS. Role of endothelin ETA receptors in the hypertension produced by 4-day L-nitroarginine methyl ester and cyclosporine treatment. Eur J Pharmacol 346: 43-50, 1998.
75. Pollock JS, Pollock DM. Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis. Curr Opin Nephrol Hypertens 17: 70-75, 2008.
76. Qiu C, Engels K, Samsell L, Baylis C. Renal effects of acute amino acid infusion in hypertension induced by chronic nitric oxide blockade. Hypertension 25: 61-66, 1995.
77. Rakugi H, Nakamaru M, Tabuchi Y, Nagano M, Mikami H, Ogihara T. Endothelin stimulates the release of prostacyclin from rat mesenteric arteries. Biochem Biophys Res Commun 160: 924-928, 1989.
78. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 306: 174-176, 1983.
79. Rebuffat P, Malendowicz LK, Neri G, Nussdorfer GG. Endothelin-11-31 acts as a selective ETA-receptor agonist in the rat adrenal cortex. Histol Histopathol 16: 535-540, 2001.
80. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-752, 1990.
81. Rehsia NS, Dhalla NS. Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. Heart Fail Rev 15: 85-101, 2010.
82. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20: 298-303, 1992.
83. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 91: 771-775, 1995.
84. Schorlemmer A, Matter ML, Shohet RV. Cardioprotective signaling by endothelin. Trends Cardiovasc Med 18: 233-239, 2008.
85. Spieker LE, Luscher TF. Protection of endothelial function. Handb Exp Pharmacol 170: 619-644, 2005.
86. Stankova J, D'Orleans-Juste P, Rola-Pleszczynski M. ET-1 induces IL-6 gene expression in human umbilical vein endothelial cells: syner-gistic effect of IL-1. Am J Physiol Cell Physiol 271: C1073-C1078, 1996.
87. Steinhorn RH. Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. J Perinatol 28, Suppl 3: S67-S71, 2008.
88. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 33: 581-585, 1999.
89. Sudjarwo SA, Hori M, Tanaka T, Matsuda Y, Okada T, Karaki H. Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction. Biochem Biophys Res Commun 200: 627-633, 1994.
90. Sventek P, Turgeon A, Schiffrin EL. Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antagonism after nitric oxide synthase inhibition with l-NAME in normal rats. Circulation 95: 240-244, 1997.
91. Takahashi K, Komaru T, Takeda S, Sato K, Kanatsuka H, Shirato K. Nitric oxide inhibition unmasks ischemic myocardium-derived vasoconstrictor signals activating endothelin type A receptor of coronary microvessels. Am J Physiol Heart Circ Physiol 289: H85-H91, 2005.
92. Teerlink JR, Carteaux JP, Sprecher U, Loffler BM, Clozel M, Clozel JP. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol Heart Circ Physiol 268: H432-H440, 1995.
93. Tirapelli CR, Fecteau MH, Honore JC, Legros E, Gobeil F, D'Orleans-Juste P. Enzymatic pathways involved in the generation of endothelin-11-31 from exogenous big endothelin-1 in the rabbit aorta. Br J Pharmacol 148: 527-535, 2006.
94. Ujiie K, Terada Y, Nonoguchi H, Shinohara M, Tomita K, Marumo F. Messenger RNA expression and synthesis of endothelin-1 along rat nephron segments. J Clin Invest 90: 1043-1048, 1992.
95. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97: 752-756, 1998.
96. Verhagen AM, Rabelink TJ, Braam B, Opgenorth TJ, Grone HJ, Koomans HA, Joles JA. Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition. J Am Soc Nephrol 9: 755-762, 1998.
97. Warner TD, Mitchell JA, de Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 13, Suppl 5: S85-S88, S102, 1989.
98. Watts SW. Endothelin receptors: what's new and what do we need to know? Am J Physiol Regul Integr Comp Physiol 298: R254-R260, 2010.
99. Watts SW, Thakali K, Smark C, Rondelli C, Fink GD. Big ET-1 processing into vasoactive peptides in arteries and veins. Vascul Pharmacol 47: 302-312, 2007.
100. Weng YH, Kuo CY, Chiu YW, Kuo ML, Liao SL. Alteration of nitric oxide gas on gene expression of endothelin-1 and endothelial nitric oxide synthase by a time- and dose-dependent manner in human endothelial cells. Chin J Physiol 52: 59-64, 2009.
101. Wolzt M, Schmetterer L, Ferber W, Artner E, Mensik C, Eichler HG, Krejcy K. Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by L-arginine. Am J Physiol Renal Fluid Electrolyte Physiol 272: F178-F182, 1997.
102. Wren AD, Hiley CR, Fan TP. Endothelin-3 mediated proliferation in wounded human umbilical vein endothelial cells. Biochem Biophys Res Commun 196: 369-375, 1993.
103. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the pro-teolytic activation of big endothelin-1. Cell 78: 473-485, 1994.
104. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.